DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-1.07%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.67B
AUM Growth
+$2.67B
(-15%)
Cap. Flow
-$330M
Cap. Flow
% of AUM
-12.39%
Top 10 Holdings %
Top 10 Hldgs %
52.23%
Holding
84
New
14
Increased
17
Reduced
20
Closed
22
Top Buys
| 1 |
Cytokinetics
CYTK
|
$88M |
| 2 |
Dynavax Technologies
DVAX
|
$67.2M |
| 3 |
Harmony Biosciences
HRMY
|
$49.9M |
| 4 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$43.8M |
| 5 |
Structure Therapeutics
GPCR
|
$42.8M |
Top Sells
| 1 |
argenx
ARGX
|
$198M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$108M |
| 3 |
Intellia Therapeutics
NTLA
|
$102M |
| 4 |
Alkermes
ALKS
|
$98M |
| 5 |
Axsome Therapeutics
AXSM
|
$77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCAX
26
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $34.8M | 1.3% | 2,000,000 +1,203,148 | +151% | +$21M |
|
|
AUTL
27
Autolus Therapeutics
AUTL
$399M
| $33.4M | 1.25% | 14,218,903 -1,053,269 | -7% | -$2.48M |
|
28
Korro Bio
KRRO
$217M
| $33.3M | 1.24% | 874,614 +24,614 | +3% | +$937K |
|
29
Terns Pharmaceuticals
TERN
$609M
| $30.9M | 1.15% | 5,576,558 | – | – |
|
30
enGene Holdings
ENGN
$236M
| $30.3M | 1.13% | 4,557,575 +1,949,942 | +75% | +$13M |
|
31
Ultragenyx Pharmaceutical
RARE
$2.89B
| $27.5M | 1.03% | +653,513 | New | +$27.5M |
|
|
ABVX
32
Abivax
ABVX
$6.12B
| $26.2M | 0.98% | 3,579,209 | – | – |
|
|
CNTA
33
Centessa Pharmaceuticals
CNTA
$2.25B
| $22.6M | 0.84% | 1,350,000 | – | – |
|
34
BridgeBio Pharma
BBIO
$9.89B
| $22.5M | 0.84% | +819,162 | New | +$22.5M |
|
35
Galapagos
GLPG
$2.07B
| $21.5M | 0.8% | +780,778 | New | +$21.5M |
|
36
Olema Pharmaceuticals
OLMA
$375M
| $20.1M | 0.75% | 3,442,833 -557,167 | -14% | -$3.25M |
|
37
MindMed
MNMD
$676M
| $19.6M | 0.73% | 2,816,594 -4,248,505 | -60% | -$29.6M |
|
38
Edgewise Therapeutics
EWTX
$1.51B
| $19M | 0.71% | 710,421 -390,115 | -35% | -$10.4M |
|
|
BCYC
39
Bicycle Therapeutics
BCYC
$511M
| $17.9M | 0.67% | 1,276,081 -2,271,920 | -64% | -$31.8M |
|
|
UPB
40
Upstream Bio, Inc. Common Stock
UPB
$923M
| $16.4M | 0.61% | +1,000,000 | New | +$16.4M |
|
41
Novavax
NVAX
$1.21B
| $16.1M | 0.6% | +2,000,000 | New | +$16.1M |
|
42
Immunocore
IMCR
$1.62B
| $15.3M | 0.57% | +519,376 | New | +$15.3M |
|
|
ORKA
43
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $14.5M | 0.54% | 750,000 -485,187 | -39% | -$9.41M |
|
44
Geron
GERN
$893M
| $14.2M | 0.53% | 4,011,287 -3,563,762 | -47% | -$12.6M |
|
|
CYBN
45
Cybin
CYBN
$176M
| $13.5M | 0.5% | 1,529,987 | – | – |
|
46
Xencor
XNCR
$580M
| $11.5M | 0.43% | 500,000 -300,000 | -38% | -$6.89M |
|
47
Aligos Therapeutics
ALGS
$73.3M
| $9.73M | 0.36% | 244,110 | – | – |
|
48
RAPT Therapeutics
RAPT
$188M
| $9.5M | 0.35% | +6,011,380 | New | +$9.5M |
|
49
Zura Bio
ZURA
$133M
| $8.21M | 0.31% | 3,283,783 | – | – |
|
50
Context Therapeutics
CNTX
$75.4M
| $7.79M | 0.29% | 7,419,355 | – | – |
|